AU2023244778A1 - Pharmaceutical composition for preventing or suppressing or treating symptoms accompanying pseudo-allergic reactions - Google Patents
Pharmaceutical composition for preventing or suppressing or treating symptoms accompanying pseudo-allergic reactions Download PDFInfo
- Publication number
- AU2023244778A1 AU2023244778A1 AU2023244778A AU2023244778A AU2023244778A1 AU 2023244778 A1 AU2023244778 A1 AU 2023244778A1 AU 2023244778 A AU2023244778 A AU 2023244778A AU 2023244778 A AU2023244778 A AU 2023244778A AU 2023244778 A1 AU2023244778 A1 AU 2023244778A1
- Authority
- AU
- Australia
- Prior art keywords
- acetamide
- sulfamoylphenyl
- phenyl
- chlorophenyl
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022060261 | 2022-03-31 | ||
| JP2022-060261 | 2022-03-31 | ||
| PCT/JP2023/013084 WO2023190826A1 (ja) | 2022-03-31 | 2023-03-30 | 偽アレルギー反応に伴う症状の予防若しくは抑制又は治療用の医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023244778A1 true AU2023244778A1 (en) | 2024-10-17 |
Family
ID=88202752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023244778A Pending AU2023244778A1 (en) | 2022-03-31 | 2023-03-30 | Pharmaceutical composition for preventing or suppressing or treating symptoms accompanying pseudo-allergic reactions |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20260000678A1 (https=) |
| EP (1) | EP4501357A1 (https=) |
| JP (1) | JPWO2023190826A1 (https=) |
| CN (1) | CN119233829A (https=) |
| AU (1) | AU2023244778A1 (https=) |
| CA (1) | CA3246964A1 (https=) |
| WO (1) | WO2023190826A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025205829A1 (ja) * | 2024-03-26 | 2025-10-02 | 国立研究開発法人国立循環器病研究センター | 脳動脈瘤の予防又は治療用の医薬組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2397480T3 (da) | 2009-02-16 | 2013-09-02 | Nippon Chemiphar Co | Diazepindionderivat |
| JP6207399B2 (ja) | 2012-01-13 | 2017-10-04 | 日本ケミファ株式会社 | Ｐ２ｘ４受容体拮抗剤 |
| EP3020707B1 (en) | 2013-07-12 | 2019-08-21 | Nippon Chemiphar Co., Ltd. | P2x4 receptor antagonist |
| AU2015296135A1 (en) | 2014-08-01 | 2017-02-16 | The Johns Hopkins University | MrgprX2/MrgprB2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions |
| US20180338980A1 (en) | 2015-06-10 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Aromatic sulfonamide derivatives |
| PL3458443T3 (pl) | 2016-05-03 | 2021-03-08 | Bayer Pharma Aktiengesellschaft | Aromatyczne pochodne sulfonamidowe |
| CA3186937A1 (en) | 2020-08-03 | 2022-02-10 | Isao Matsuoka | Pharmaceutical composition for preventing, suppressing, or treating symptoms associated with allergic reaction |
-
2023
- 2023-03-30 JP JP2024512770A patent/JPWO2023190826A1/ja active Pending
- 2023-03-30 CA CA3246964A patent/CA3246964A1/en active Pending
- 2023-03-30 CN CN202380041406.1A patent/CN119233829A/zh active Pending
- 2023-03-30 WO PCT/JP2023/013084 patent/WO2023190826A1/ja not_active Ceased
- 2023-03-30 US US18/851,792 patent/US20260000678A1/en active Pending
- 2023-03-30 EP EP23780834.0A patent/EP4501357A1/en active Pending
- 2023-03-30 AU AU2023244778A patent/AU2023244778A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023190826A1 (ja) | 2023-10-05 |
| US20260000678A1 (en) | 2026-01-01 |
| JPWO2023190826A1 (https=) | 2023-10-05 |
| CN119233829A (zh) | 2024-12-31 |
| CA3246964A1 (en) | 2025-07-09 |
| EP4501357A1 (en) | 2025-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8921357B2 (en) | Pyridazinone derivatives | |
| EP2049531B1 (de) | 2-(heterocyclylbenzyl)-pyridazinonderivate | |
| US8367668B2 (en) | Pyridazinone derivatives | |
| US8173653B2 (en) | Pyridiazinone derivatives for the treatment of tumours | |
| CN1898209A (zh) | 葡糖激酶调节剂吡啶羧酸衍生物 | |
| CN101039677A (zh) | 利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法 | |
| CN1575284A (zh) | 作为激酶抑制剂的取代的三唑二胺衍生物 | |
| ES2396301T3 (es) | Derivados de piridazinona | |
| CN1711094A (zh) | Src家族非受体酪氨酸激酶抑制剂和吉西他滨的组合产品 | |
| CN1056879A (zh) | 吡咯衍生物及其制备方法 | |
| MX2010011454A (es) | Derivados de piridazinona. | |
| CN1882588A (zh) | A2b腺苷受体拮抗剂 | |
| AU2021320957B2 (en) | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | |
| ES2548517T3 (es) | Derivados de 1-acildihidropirazol | |
| CN1950085A (zh) | 作为趋化因子受体调节剂的3－(4－杂芳基环己基氨基)环戊烷羧酰胺 | |
| EP4501357A1 (en) | Pharmaceutical composition for preventing or suppressing or treating symptoms accompanying pseudo-allergic reactions | |
| AU2006275161A1 (en) | Quadratic acid II derivatives | |
| JPWO2023190826A5 (https=) | ||
| WO2009143945A1 (de) | Dihydropyrazolderivate als tyrosinkinase modulatoren zur behandlung von tumoren | |
| CN1922160A (zh) | 化合物 | |
| ZA200901997B (en) | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | |
| CN101568534A (zh) | 用于治疗glk介导的疾病的苯甲酰基氨基杂环化合物 |